Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

#### **DEXTROMETHORPHAN** with QUINIDINE

Generic	Brand	HICL	GCN	Exception/Other
DEXTROMETHORPHAN/ QUINIDINE	NUEDEXTA	37278		

### **GUIDELINES FOR USE**

1. Does the patient have a diagnosis of pseudobulbar affect (PBA)?

If yes, **approve for 12 months by HICL for #2 per day per month.** If no, do not approve. **DENIAL TEXT:** Our guideline for **DEXTROMETHORPHAN with QUINIDINE** requires a diagnosis of pseudobulbar affect (PBA).

# RATIONALE

Ensure that Nuedexta is used solely for its FDA approved indication and in patients for whom it has been determined to be safe and efficacious.

## FDA APPROVED INDICATION

Nuedexta is indicated for treatment of pseudobulbar affect (PSA).

### REFERENCES

- Avanir Pharmaceuticals, Inc. Nuedexta package insert. Aliso Viejo, CA. January 2015.
- Miller A, Pratt H, and Schiffer R. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011; 11(7) 1077-1088:
- National Stroke Association. Pseudobulbar affect and stroke. Stroke Clinical Updates. Volume XV, Issue 1: January/February 2005.
- Pioro E. Current concepts in pharmacotherapy of pseudobulbar affect. Drugs 2004; 71 (9): 1192-1207.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 05/01/15 Created: 02/11 Client Approval: 03/15

P&T Approval: 01/15

Copyright © 2019 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.